Bookmark
Forward
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
Cancer cell 2022 Nov 14Sizes of these terms reflect their relevance to your search.
Sklavenitis-Pistofidis et al. report clinical and correlative results of a single-arm phase II trial of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering myeloma. The authors explore the interactions between the genetics of the plasma cell clone and the immune microenvironment as potential biomarkers of treatment susceptibility and efficacy. Copyright © 2022 Elsevier Inc. All rights reserved.
Citation
Kylee H Maclachlan, Alexander M Lesokhin. Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma? Cancer cell. 2022 Nov 14;40(11):1270-1272
Mesh Tags
Substances
PMID: 36379204
View Full Text
